Weakness in derma segment led to tepid Q4: Glenn Saldanha, Glenmark Pharma
  • WebDesk BTVI
  • May 30 2019

Glenn Saldanha, Chairman and MD of Glenmark Pharmaceuticals, said Q4 revenue grew 12% whereas FY19 revenue grew 8-9%. He said while business in Asia and African market was robust in FY19, pricing environment was weak in dermatology segment for US market. He says India will be a major API supplier globally in the next 5 years. Saldanha added that he expects the company’s margin to be in the 16%-17% range with a 10-12% growth going forward.